| Autor: |
MUNEERA SAEED SAAD ALQAHTANI, EBTHAL HASSAN K. AL-GHAZWI, ABDALRHMAN NABIL T. BOKHARI, MOHAYA KHANFOUR ALRASHIDI, HASHIM HUSSAIN ALALI, AHMED OMAR ALROWAILA, JOUD AMER ALKWILDY, ELAF TALIB MESHREF, YOUSUF LOAI F RAMADAN, S. ALATAWI, ASMA MOHAMMED, ASRAR FAWAZ ALANAZI, MAZEN BISHARAH |
| Rok vydání: |
2022 |
| Zdroj: |
UTTAR PRADESH JOURNAL OF ZOOLOGY. :177-188 |
| ISSN: |
0256-971X |
| DOI: |
10.56557/upjoz/2022/v43i243312 |
| Popis: |
Background: In the developed countries, pulmonary thromboembolism associated with pregnancy (VTE) continues to be the principal cause of direct maternal death. Despite thorough treatment and preventative recommendations from several national authorities, reductions in mortality due to VTE have been negligible. Anticoagulation is still the cornerstone of prenatal care and has to be given to all patients with proven or high-risk PE. The preferred medication is low molecular weight heparin (LMWH), which has a known pharmacodynamic profile. Despite the massive utilization of these drugs there is actually little evidence supporting their efficiency in recurrent pregnancy loss reduction. Objectives: The study aims to summarize current evidences regarding the usage of anticoagulants and thrombolytics in Pregnancy. Methods: For article selection, the PubMed database and EBSCO Information Services were used. All relevant articles relevant with our topic and other articles were used in our review. Other articles that were not related to this field were excluded. The data was extracted in a specific format that was reviewed by the group members. Conclusion: A common cause of maternal death, pulmonary embolism-related fatalities still occur often in pregnant women with pulmonary embolism. One-third of pregnant women with pulmonary embolism and hemodynamic failure were reported to undergo systemic thrombolysis. There is an urgent need to improve prevention and care techniques for this vulnerable patient population. LMWHs are widely used for several different purposes as well as for the treatment and prevention of VTE during pregnancy and puerperium. Although the medicine has been found to be both safe and effective, there is no scientific proof to support its usage for all indications. In pregnant women with thrombophilia who are at high risk of developing these issues, prenatal prophylactic dalteparin does not prevent venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy difficulties and is linked to an increased risk of mild bleeding. Enoxaparin may not offer any meaningful benefits to people suffering from recurrent abortion. However, in one study, the miscarriage rate was significantly lower when enoxaparin was used compared with untreated controls. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
